Helix Biopharma Corp Stock Net Income
| HBPCF Stock | USD 1.73 0.00 0.00% |
Helix BioPharma technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.
Helix BioPharma's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Helix BioPharma's valuation are provided below:Helix BioPharma Corp does not presently have any fundamental trends for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Helix |
Helix BioPharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Helix BioPharma's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Helix BioPharma.
| 11/04/2025 |
| 02/02/2026 |
If you would invest 0.00 in Helix BioPharma on November 4, 2025 and sell it all today you would earn a total of 0.00 from holding Helix BioPharma Corp or generate 0.0% return on investment in Helix BioPharma over 90 days. Helix BioPharma is related to or competes with Relief Therapeutics, Relief Therapeutics, Arch Biopartners, Zivo Bioscience, and Vicapsys Life. Helix BioPharma Corp. operates as an immune-oncology company in Canada More
Helix BioPharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Helix BioPharma's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Helix BioPharma Corp upside and downside potential and time the market with a certain degree of confidence.
Helix BioPharma Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Helix BioPharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Helix BioPharma's standard deviation. In reality, there are many statistical measures that can use Helix BioPharma historical prices to predict the future Helix BioPharma's volatility.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Helix BioPharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Helix BioPharma Corp Backtested Returns
We have found three technical indicators for Helix BioPharma Corp, which you can use to evaluate the volatility of the firm. The company retains a Market Volatility (i.e., Beta) of 0.0, which attests to not very significant fluctuations relative to the market. the returns on MARKET and Helix BioPharma are completely uncorrelated.
Auto-correlation | 1.00 |
Perfect predictability
Helix BioPharma Corp has perfect predictability. Overlapping area represents the amount of predictability between Helix BioPharma time series from 4th of November 2025 to 19th of December 2025 and 19th of December 2025 to 2nd of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Helix BioPharma Corp price movement. The serial correlation of 1.0 indicates that 100.0% of current Helix BioPharma price fluctuation can be explain by its past prices.
| Correlation Coefficient | 1.0 | |
| Spearman Rank Test | 1.0 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Helix BioPharma Corp reported net income of (6.56 Million). This is 101.92% lower than that of the Biotechnology sector and 109.37% lower than that of the Health Care industry. The net income for all United States stocks is 101.15% higher than that of the company.
Helix Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Helix BioPharma's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Helix BioPharma could also be used in its relative valuation, which is a method of valuing Helix BioPharma by comparing valuation metrics of similar companies.Helix BioPharma is currently under evaluation in net income category among its peers.
Helix Fundamentals
| Return On Equity | -12.06 | |||
| Return On Asset | -1.04 | |||
| Current Valuation | 30.65 M | |||
| Shares Outstanding | 200.02 M | |||
| Shares Owned By Insiders | 18.35 % | |||
| Shares Owned By Institutions | 13.10 % | |||
| Number Of Shares Shorted | 2.27 K | |||
| Price To Earning | (6.52) X | |||
| Price To Book | 134.72 X | |||
| EBITDA | (6.53 M) | |||
| Net Income | (6.56 M) | |||
| Cash And Equivalents | 1.88 M | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 2.88 M | |||
| Debt To Equity | 0.03 % | |||
| Current Ratio | 0.69 X | |||
| Book Value Per Share | (0.01) X | |||
| Cash Flow From Operations | (6.51 M) | |||
| Short Ratio | 3.83 X | |||
| Earnings Per Share | (0.04) X | |||
| Beta | -0.56 | |||
| Market Capitalization | 29.76 M | |||
| Total Asset | 3.73 M | |||
| Working Capital | 20.41 M | |||
| Current Asset | 22.72 M | |||
| Current Liabilities | 2.32 M | |||
| Z Score | 8.7 | |||
| Net Asset | 3.73 M |
About Helix BioPharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Helix BioPharma Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Helix BioPharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Helix BioPharma Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| VGIAX | Vanguard Growth And | |
| XAR | SPDR SP Aerospace | |
| XAR | SPDR SP Aerospace | |
| XAR | SPDR SP Aerospace | |
| ASML | ASML Holding NV |
Other Information on Investing in Helix Pink Sheet
Helix BioPharma financial ratios help investors to determine whether Helix Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Helix with respect to the benefits of owning Helix BioPharma security.